Publications by authors named "Kyle Beckwith"

Claim this Profile
A
A framework integrating multiscale in-silico modeling and experimental data predicts CD33CAR-NK cytotoxicity across target cell types.
Saeed Ahmad, Kun Xing, Harshana Rajakaruna, William C Stewart, Kyle A Beckwith

bioRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
Adam S Kittai, Ying Huang, Kyle A Beckwith, Seema A Bhat, David A Bond

Am J Hematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
Adam S Kittai, Cecelia Miller, Daniel Goldstein, Ying Huang, Lynne V Abruzzo, Kyle Beckwith

Blood· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.
Priscilla Do, Kyle A Beckwith, Carolyn Cheney, Minh Tran, Larry Beaver

J Immunol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib treatment improves T cell number and function in CLL patients.
Meixiao Long, Kyle Beckwith, Priscilla Do, Bethany L Mundy, Amber Gordon

J Clin Invest· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Joseph A Fraietta, Kyle A Beckwith, Prachi R Patel, Marco Ruella, Zhaohui Zheng

Blood· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toll-Like Receptors and Dectin-1, a C-Type Lectin Receptor, Trigger Divergent Functions in CNS Macrophages.
John C Gensel, Yan Wang, Zhen Guan, Kyle A Beckwith, Kaitlyn J Braun

J Neurosci· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Zachary A Hing, Rose Mantel, Kyle A Beckwith, Daphne Guinn, Erich Williams

Blood· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetraspanins as therapeutic targets in hematological malignancy: a concise review.
Kyle A Beckwith, John C Byrd, Natarajan Muthusamy

Front Physiol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.
Ta-Ming Liu, Yonghua Ling, Jennifer A Woyach, Kyle Beckwith, Yuh-Ying Yeh

Blood· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.
Erin Hertlein, Kyle A Beckwith, Gerard Lozanski, Timothy L Chen, William H Towns

PLoS One· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Jason A Dubovsky, Kyle A Beckwith, Gayathri Natarajan, Jennifer A Woyach, Samantha Jaglowski

Blood· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis